Drug Disposition in Liver Transplant Patients
NIH
12/1988 – 11/1991 ($562,486)
12/1988 – 11/1991 ($562,486)
Co-investigator
PI – Gilbert J. Burckart
PI – Gilbert J. Burckart
Clinical Trial of FK 506 in Liver and Renal Transplant Patients
Fujisawa Pharmaceuticals
10/1988 to 9/1990 ($90,000)
10/1988 to 9/1990 ($90,000)
Co-investigator
PI – Starzl
PI – Starzl
Analysis of FK 506 in Transplant Patients
Fujisawa Pharmaceuticals
6/1989 – 5/1991 ($80,000)
6/1989 – 5/1991 ($80,000)
Co-investigator
PI – Starzl
PI – Starzl
Interaction of FK 506 and Fluconazole
Pfizer Pharmaceuticals, 6/1992 to 5/1993
($100,000)
($100,000)
Co-investigator
PI – Venkataramanan
PI – Venkataramanan
Disposition in Liver Transplant Patients
NIH
7/94-6/1995 ($131,560)
1995-1996 ($136,783)
7/94-6/1995 ($131,560)
1995-1996 ($136,783)
Co-investigator
PI – Burckart
PI – Burckart
FK 506 Kinetics in Patients with Liver Disease
Fujisawa Pharmaceuticals
1994-1997 ($65,621) Supplement $10,000.
1994-1997 ($65,621) Supplement $10,000.
Co-investigator
PI – Venkataramanan
PI – Venkataramanan
FK 506 Studies-Data Analysis
Fujisawa Pharmaceuticals, 1995 ($10,000)
Co-investigator
PI – Venkataramanan
PI – Venkataramanan
FK 506 Research Studies
Fujisawa Pharmaceuticals, 1996 ($30,000)
Co-investigator
PI – Venkataramanan
PI – Venkataramanan
Field Evaluation of the Abbot IMX Tacrolimus II assay: Correlation Study
Abbot Laboratories, 1996 ($20,886)
Co-investigator
Field Evaluation of the INCSTAR ELISA Tacrolimus Assay: Correlation Study
INCSTAR
($108,549)
($108,549)
Co-investigator
Pharmacokinetics of Mycophenolate Mofetil in Liver Transplant Patients
Roche Pharmaceuticals, 5/1997 – 12/1999
($61,398)
($61,398)
Co-investigator
Prospective randomized trial Prograf/Prednisone/MMF versus Prograf/Prednisone
Roche Pharmaceuticals 1995-97
($150,000)
($150,000)
Co-PI
PI – Fung
PI – Fung
Prograf Kinetic Studies
Fujisawa, 1997
($10,000)
($10,000)
PI
Prograf MMF kinetic studies
Fujisawa, 1998
($10,000)
($10,000)
PI
Long-Term Results of Pediatric Liver Transplantation
Fujisawa, 1998
($10,000)
($10,000)
Co-PI
PI – Jorge Reyes
PI – Jorge Reyes
Open Label Study of Neoral as Primary Immunsuppressant Therapy in Transplant Patients Who Are Unable to Maintain Satisfactory Immunosuppression on Prograf (Tacrolimus)
Novartis Pharmaceuticals
1/1998-12/1999
($83,200)
1/1998-12/1999
($83,200)
PI
An Open-Label, Active-Controlled Study to Evaluate the Use of CellCept (Mycophenolate Mofetil, MMF) in Post-Liver Transplant Patients with Renal Impairment Who Are Currently on FK 506 NR15715
Roche Pharmaceuticals, 12/1998-12/2000
($141,627)
($141,627)
PI
Predicting Outcome in Alcoholic Liver Transplant Recipient
NIH K08AA00257/01
June 1998-May 2003
($659,791)
June 1998-May 2003
($659,791)
Consultant
PI Andrea DiMartini
PI Andrea DiMartini
Long-term outcome of Immunosuppression
Fujisawa
1999: ($25,000)
2000: Unrestricted
1999: ($25,000)
2000: Unrestricted
Use of sirolimus for Prograf-related nephrotoxicity
Wyeth, 2001-2002
($ 57,000)
($ 57,000)
Multicenter study of sirolimus (Rapamune, Rapamycin) 0468E1-220-US: A Phase II, Open-Label, Concentration-Controlled, Randomized Study of Conventional-Dose tacrolimus plus corticosteroids compared with Reduced-Dose tacrolimus plus sirolimus and corticosteroids in recipients of orthotopic liver allografts
Wyeth-Ayerst, 2001
($ 250,000)
($ 250,000)
Co PI
Sirolimus for primary pancreatic transplantation
Wyeth
($ 5,000)
($ 5,000)
Exploration of clyclosporine C2 monitoring in liver transplant patient
Novartis
($ 128,000).
($ 128,000).
PI
Multicenter trial in Entercavir v/s Adefovir Comparison of the efficacy and safety of Entecavir v/s Adefovir in subjects chronically infected with heapatitis B virus
Bristol-Myer Squibb
($ 72,000)
($ 72,000)
PI
Multicenter use of Rapamycin for tacromlimus related nephrotoxicity in post liver transplant patients
Wyeth
($ 250,000)
($ 250,000)
Co-investigator
Pharmacokinetics of intravenous / oral MMF and oral Tacrolimus in live donor and deceased donor liver transplant patients
Hoffmann-La Roche Inc. ($ 141,000)
PI
A bioequivalence study comparing ganciclovir from the valganciclovir syrup formulation and the commercial valganciclovir 450mg tablet (Valcyte®) at a dose of 900mg in kidney transplant recipients
Roche
($ 115,652)
($ 115,652)
PI
A phase IIB, randomized, multicenter, open-label, concentration-controlled, safety study of ISA247 and tacrolimus (Prograf®) in de-novo renal transplant patients
Isotechnika Inc.
($ 197,613)
($ 197,613)
PI
